Literature DB >> 3884549

Should the criteria for species distinction in adenoviruses be reconsidered? Evidence from canine adenoviruses 1 and 2.

C A Whetstone.   

Abstract

Four strains of canine adenovirus type 1 (CAV-1) and two strains of canine adenovirus type 2 (CAV-2) were examined by restriction enzyme analysis. In all cases, CAV-1 could be readily differentiated from CAV-2. Additionally, monoclonal antibodies were prepared against the Mirandola and Manhattan strains of CAV-1 and CAV-2, respectively. 18 of 36 monoclonal antibodies from the CAV-1 fusion and 77 of 160 monoclonal antibodies from the CAV-2 fusion were type-specific by an indirect fluorescent-antibody technique. Moreover, among those type-specific monoclonal antibodies, 13 of the 18 CAV-1 antibodies and 39 of the 77 CAV-2 antibodies specifically neutralized only the homologous virus in vitro. These data, along with other evidence from the literature, suggest that not only should CAV-1 and CAV-2 be recognized as distinct species in the genus mastadenovirus of the family Adenoviridae, but also that the major criterion of species distinction in that family, namely neutralization, should be reconsidered.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3884549     DOI: 10.1159/000149594

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  4 in total

1.  Characterization of the genome of a vaccine strain of canine adenovirus type 1.

Authors:  Y C Liu; M G Abouhaidar; S Sira; J B Campbell
Journal:  Virus Genes       Date:  1988-10       Impact factor: 2.332

2.  Genotypic differences between the mouse adenovirus strains FL and K87.

Authors:  C Hamelin; G Lussier
Journal:  Experientia       Date:  1988-01-15

3.  Genome typing of mouse adenoviruses.

Authors:  C Hamelin; C Jacques; G Lussier
Journal:  J Clin Microbiol       Date:  1988-01       Impact factor: 5.948

4.  Immunological and molecular comparison of fowl adenovirus serotypes 4 and 10.

Authors:  K Erny; J Pallister; M Sheppard
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.